Phase
Condition
Influenza
Respiratory Syncytial Virus (Rsv) Infection
Common Cold
Treatment
Cycloferon
Placebo
Clinical Study ID
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male and female subjects aged 18 to 65 years inclusive.
Written informed consent.
Co-living with persons who has developed influenza or other acute respiratory viralinfection, diagnosed no more than 3 days ago.
No signs of acute respiratory viral infection, influenza or COVID-19 at the time ofinclusion in the study.
For women with preserved reproductive potential - a negative pregnancy test andconsent to use approved methods of contraception during the entire period ofparticipation in the study; for men - consent to use approved methods ofcontraception during the entire period of participation in the study and for 3 weeksafter the end of the study.
Exclusion
Exclusion Criteria:
Known or suspected hypersensitivity to meglumine acridone acetate and/or any othercomponent of the drug/placebo.
Lactose intolerance
Diseases of the digestive system in the acute stage (erosions, gastric and/orduodenal ulcers, gastritis and duodenitis).
History of allergic reactions.
Decompensated liver cirrhosis.
Diseases of the thyroid gland.
Congenital or acquired immunodeficiency.
Signs of acute respiratory viral infection, influenza or COVID-19 at the time ofinclusion.
Positive result of a rapid test for the presence of SARS-CoV-2 at the time ofscreening.
Vaccination to prevent COVID-19 and/or influenza within 6 months before screening,planned vaccination during a clinical trial.
History of positive test result for HIV types 1 or 2.
Pregnancy or breastfeeding period (for women).
Alcoholism, drug addiction, substance and/or drug abuse in history and/or at thetime of screening.
Participation in another clinical trial within 3 months before inclusion.
Subject is already receiving cycloferon.
Subject is receiving prohibited therapy or was receiving it within 30 days prior toscreening.
Failure to observe the subject during the study period.
Other reasons that, in the opinion of the researcher, prevent the subject fromparticipating in the study or create an unreasonable risk (for example, a history ofautoimmune diseases, etc.).
Study Design
Connect with a study center
Research Center for Eco-safety, Ltd.
Saint Petersburg, 196143
Russian FederationSite Not Available
City Outpatient Clinic #117
Saint-Petersburg,
Russian FederationSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.